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rural southwestern United States (10) 
and a strain of pathogenic B. elizabe-
thae, a bacteria that can cause human 
endocarditis, in the Huayllacallán Val-
ley in Peru (3).
Because most identified Barton-
ella spp. have been reported as infec-
tious agents for humans, our results 
should prompt public health concern. 
However, our findings require further 
investigation about the pathogenic-
ity of these Bartonella genotypes. 
The detection of both pathogens in 
intradomestic and peridomestic areas 
where humans are in close contact 
with rodents could indicate that the 
incidence of both diseases in humans 
from Echarate District might be un-
derestimated.
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Buruli Ulcer  
Disease in Republic 
of the Congo
To the Editor: Buruli ulcer, which 
is caused by the Mycobacterium ulcer-
ans bacterium, is a severe disabling 
necrotic disease of the skin, occur-
ring mainly in swampy rural areas of 
western and central Africa. This tropi-
cal disease is neglected, despite being 
the third most common mycobacterial 
disease of humans, after tuberculosis 
and leprosy. The disease has become 
substantially more frequent over the 
past decade, particularly around the 
Gulf of Guinea, and has been detected 
or suspected in at least 31 countries 
(1). Clinical diagnosis of Buruli ulcer 
disease should be confirmed by PCR, 
as recommended by the World Health 
Organization (WHO); and case-pa-
tients should be treated with rifampin/
streptomycin daily for 8 weeks (thera-
py available since 2004), combined, if 
necessary, with surgery.
Although confirmed cases of 
Buruli ulcer disease have been re-
ported in all countries neighboring 
the Republic of the Congo (hereafter 
called Congo) (2–4), only 1 report of 
a confirmed case in Congo has been 
published (5) (Figure, panel A). Dur-
ing 2007–2012, a total of 573 clinical 
cases of Buruli ulcer disease were re-
ported to WHO by the National Lep-
rosy, Buruli Ulcer and Yaws Control 
Program in Congo. We report 108 
cases (19% of all cases reported) that 
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were confirmed, in accordance with 
WHO recommendations, by quan-
titative PCR, the most sensitive and 
specific testing method available (6).
The National Leprosy, Buruli Ul-
cer, and Yaws Control Program, with 
the support of the Raoul Follereau 
Foundation (Paris, France), performed 
passive and active surveillance of Bu-
ruli ulcer in Congo during 2007–2012. 
Fine-needle aspirate or swab samples 
were obtained from patients with sus-
pected Buruli ulcer and sent to Angers 
University Hospital (Angers, France) 
for confirmation by quantitative PCR 
as described (6,7). Of the 283 samples 
analyzed, 114 (40%) from 108 differ-
ent patients were PCR positive. Of the 
114 PCR-positive samples, 20 (18%) 
were fine-needle aspirate samples and 
94 (82%) were swab samples (at least 
2 swabs/lesion). The 108 case-patients 
included 60 (56%) female and 48 
(44%) male patients; 56% of the case-
patients were <15 years of age. The 
most common clinical form of the 
disease (86% of cases) was the ulcer-
ative stage with edema or plaque. All 
confirmed Buruli ulcer case-patients 
were treated in accordance with WHO 
recommendations (8): antibiotic treat-
ment (rifampin/streptomycin) plus 
surgery if necessary. All patients with 
nonconfirmed cases were treated ac-
cording to the alternative diagnosis 
reached by the clinician.
Our findings show that Buruli ul-
cer disease affects persons in several 
of Congo’s administrative divisions 
(Figure, panel B); of the 108 patients, 
77 (71%) were from Kouilou Depart-
ment (Figure, panel C). The village of 
residence was recorded for 55of these 
77 patients, 46 (84%) of whom lived 
in 9 villages along the Kouilou River, 
encompassing an area of ≈50 km × 20 
km: Madingo-Kayes, Kanga, Louk-
ouala, Mfilou, Koubotchi, Mboukou-
massi, Tchisseka, Magne, and Loaka 
villages. This disease-endemic area in-
cludes 2 lakes, Dinga and Nanga, both 
of which are fed by the Kouilou River. 
The remaining 31 (29%) confirmed 
patients (i.e., those not living in Kou-
ilou Department) lived in Niari De-
partment (9%), Bouenza Department 
(6.5%), Pool Department (3%), or Cu-
vette Department (5.5%) or in Pointe 
Noire Commune (2%) or Brazzaville 
Commune (3%) (Figure, panel B).
The distribution of Buruli ulcer 
cases in Congo is unusual. The Kou-
ilou River region was most affected, 
but several other areas, all in southern 
Congo, have confirmed Buruli ulcer 
patients. Cuvette Department is the 1 
exception; although it is in northeast-
ern Congo, this department did have a 
cluster of cases. The cases in Cuvette 
were identified (and the infections 
were diagnosed and treated) during ac-
tive research into Buruli ulcer during 
2009–2010. (Note that there has been 
no survey in this region since 2010.)
Buruli ulcer is also endemic in 
some areas of the countries neighbor-
ing Congo. In the Democratic Repub-
lic of the Congo, the disease is highly 
endemic in the Bas Congo region, 
which shares a border with depart-
ments in southern Congo where the 
disease is endemic (9). By contrast, 
the small cluster of cases diagnosed in 
Cuvette Department in northeastern 
Congo seems to be isolated from oth-
er areas where the disease is known to 
be endemic.
Figure.	Buruli	ulcer–endemic	areas	in	the	Republic	of	the	Congo	(RC)	and	neighboring	countries.	A)	Buruli	ulcer	cases	have	been	reported	
in	all	 countries	neighboring	RC.	CAR,	Central	African	Republic;	DR	Congo,	Democratic	Republic	of	 the	Congo.	B)	RC	 (representing	
the	white	 area	 in	 panel	A).	The	numbers	 indicate	 the	7	departments	 or	 communes	 (of	 12	 total)	where	PCR-positive	 cases	of	Buruli	
ulcer	disease	were	diagnosed.	1,	Kouilou	Department;	2	Pointe	Noire	Commune;	3,	Niari	Department;	4,	Bouenza	Department;	5,	Pool	
Department;	6,	Brazzaville	Commune;	7,	Cuvette	Department.	C)	Kouilou	Department	(department	1	in	panel	B).	Most	Buruli	ulcer	case-
patients	from	Kouilou	Department	were	living	close	to	the	Kouilou	River.	Stars	indicate	locations	of	health	centers	that	treat	Buruli	ulcer	
disease;	circles	indicate	areas	where	persons	with	Buruli	ulcer	disease	were	identified.	A	color	version	of	this	figure	is	available	online	
(wwwnc.cdc.gov/eid/article/20/6/13-1498-F1.htm)
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M. ulcerans is known to be asso-
ciated with wetlands, and the Kouilou 
River environment is certainly suitable 
for its spread (10). Identification of this 
zone as a high-risk area for Buruli ulcer 
disease will help the Ministry of Health 
improve early detection, biological 
confirmation, and treatment programs. 
In the other regions, active and contin-
uous surveillance is necessary to estab-
lish a detailed map of the villages and 
areas where Buruli ulcer disease is en-
demic; such information would enable 
the implementation of targeted control 
activities. However, active surveillance 
in Congo has substantially declined 
since 2011. Our findings support the 
reactivation of such surveillance cam-
paigns to ensure the early identification 
and confirmation of Buruli ulcer cases 
and to improve patient management.
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Rapid Metagenomic 
Diagnostics for  
Suspected  
Outbreak of  
Severe Pneumonia
To the Editor: Recent outbreaks 
of severe pneumonia or acute respira-
tory distress syndrome (ARDS) have 
attracted much public interest. Given 
current awareness levels, clinical per-
sonnel and health officials must rapid-
ly and adequately respond to suspected 
outbreaks to prevent public disturbanc-
es. We report a case that highlights the 
potential of next-generation sequenc-
ing (NGS) to complement convention-
al diagnostics in such scenarios.
On March 29, 2013, a police of-
ficer (patient 1) was admitted to the 
emergency department of the Univer-
sity Medical Centre Hamburg–Eppen-
dorf in Hamburg, Germany, because 
of ARDS. The patient was given me-
chanical ventilation; all diagnostic 
test results for pathogens commonly 
known to cause pneumonia were 
negative (www.virus-genomics.org/
supplementaries/EID1406.pdf). Al-
though treatment with antimicrobial 
drugs was immediately initiated, the 
patient died 6 days later of multiple 
organ failure.
On April 5, a second police offi-
cer (patient 2) from the same county 
was admitted to the same emergency 
department because of ARDS. He 
was transferred to the intensive care 
unit and given mechanical ventilation. 
Similar to the situation for patient 1, 
diagnostic test results were negative, 
prompting the news media to suspect 
an outbreak of a novel or mutated 
virus (1,2). Especially because of si-
multaneous outbreaks of avian influ-
enza and infections with Middle East 
respiratory syndrome coronavirus in 
other parts of the world, these reports 
caused serious concern among the 
public and health officials.
After the death of patient 1 and hos-
pitalization of patient 2, we subjected 
